Trials / Completed
CompletedNCT00664170
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Mast Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare an injectable emulsion form of docetaxel to Taxotere in patients with advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANX-514 | 75 mg/m\^2 |
| DRUG | docetaxel | 75 mg/m\^2 |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2008-04-22
- Last updated
- 2009-05-28
Locations
13 sites across 3 countries: United States, Argentina, Estonia
Source: ClinicalTrials.gov record NCT00664170. Inclusion in this directory is not an endorsement.